BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38244660)

  • 21. Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer.
    Liu L; Xu X; Liang X; Zhang X; Wen J; Chen K; Su X; Ma Y; Teng Z; Lu G; Xu J
    J Colloid Interface Sci; 2021 Jun; 591():211-220. PubMed ID: 33609893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.
    Yuan G; Liu Z; Wang W; Liu M; Xu Y; Hu W; Fan Y; Zhang X; Liu Y; Si G
    J Nanobiotechnology; 2023 Feb; 21(1):68. PubMed ID: 36849981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.
    Lym JS; Nguyen QV; Ahn da W; Huynh CT; Jae HJ; Kim YI; Lee DS
    Acta Biomater; 2016 Sep; 41():253-63. PubMed ID: 27184404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.
    Li H; Liang C; Kuang D; Huang G; Zhang M; Chen P; Zheng Q; Xu W; Ren J; Han X; Duan X
    Cancer Biol Ther; 2023 Dec; 24(1):2166335. PubMed ID: 36751709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma.
    Bayraktar Y; Balkanci F; Kayhan B; Uzunalimoglu B; Gokoz A; Ozisik Y; Gurakar A; Van Thiel DH; Firat D
    Hepatogastroenterology; 1996; 43(9):681-7. PubMed ID: 8799415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
    Nishikawa H; Kita R; Kimura T; Osaki Y
    Anticancer Res; 2014 Dec; 34(12):6877-86. PubMed ID: 25503113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TACE versus TAE as therapy for hepatocellular carcinoma.
    Pleguezuelo M; Marelli L; Misseri M; Germani G; Calvaruso V; Xiruochakis E; Manousou P; Burroughs AK
    Expert Rev Anticancer Ther; 2008 Oct; 8(10):1623-41. PubMed ID: 18925854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
    Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU
    Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.
    Nam HC; Jang B; Song MJ
    World J Gastroenterol; 2016 Oct; 22(40):8853-8861. PubMed ID: 27833376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intra-arterial contrast-enhanced ultrasound (IA CEUS) for localization of hepatocellular carcinoma (HCC) supply during transarterial chemoembolization (TACE): a case series.
    Lekht I; Nayyar M; Luu B; Guichet PL; Ho J; Ter-Oganesyan R; Katz M; Gulati M
    Abdom Radiol (NY); 2017 May; 42(5):1400-1407. PubMed ID: 28008454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Huang K; Zhou Q; Wang R; Cheng D; Ma Y
    J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering orthotopic tumor spheroids with organ-specific vasculatures for local chemoembolization evaluation.
    Gao Y; Xiao J; Chen Z; Ma Y; Liu X; Yang D; Leo HL; Yu H; Kong J; Guo Q
    Biomater Sci; 2023 Mar; 11(6):2115-2128. PubMed ID: 36723179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
    Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
    Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Wu X; Chapiro J; Malhotra A; Kothary N
    J Vasc Interv Radiol; 2021 Jan; 32(1):2-12.e1. PubMed ID: 33160827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of glass membrane emulsification device in conventional transarterial chemoembolization for hepatocellular carcinoma: a preliminary study.
    Ishikawa T; Kodama E; Kobayashi T; Azumi M; Nozawa Y; Iwanaga A; Sano T; Honma T
    Ann Palliat Med; 2023 May; 12(3):448-457. PubMed ID: 36786095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.